PVI to Prevent S. Aureus SSI After Fixation of HELEF (POTENT Study)

Sponsor
Loreen Herwaldt (Other)
Overall Status
Recruiting
CT.gov ID
NCT05763602
Collaborator
Indiana University (Other), University of Utah (Other), Washington University School of Medicine (Other), University of Texas (Other), Emory University (Other), PDI Healthcare (Other), Centers for Disease Control and Prevention (U.S. Fed)
2,000
6
2
32.5
333.3
10.3

Study Details

Study Description

Brief Summary

The purpose of this study is to see whether applying povidone iodine (PVI) to the noses of patients undergoing lower extremity (leg, ankle, or foot) orthopedic fixation procedures of high-energy lower extremity fractures (HELEF) will decrease the patients' risk of surgical site infections (SSI), particularly those caused by Staphylococcus aureus.

Condition or Disease Intervention/Treatment Phase
  • Drug: povidone-iodine topical ointment
Phase 4

Detailed Description

These patients are at high risk of SSI but given the rapidity with which they need their operations, interventions that take time are difficult or impossible to use in this patient population. This study will involve identifying patients with HELEF and applying PVI to their nares within 60 minutes before their surgical incisions are made and again approximately 12 hours after the first dose. The investigators will abstract information from the patients' medical records about their demographics, underlying illnesses, injury severity, the surgical procedures, and SSI for the 6 months following their operations and the investigators will see them during their routinely scheduled visit at about 6 months to ask them whether they were treated for SSI by providers outside of our system. For patients who do not return for follow up, the investigators will try to contact them to determine if they had signs or symptoms of SSI or were treated for SSI outside of our system.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
2000 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Intranasal Povidone Iodine (PVI) to Prevent Staphylococcus Aureus Surgical Site Infections After Operative Procedures to Fix High-Energy Lower Extremity Fractures (POTENT Study)
Actual Study Start Date :
Sep 15, 2022
Anticipated Primary Completion Date :
Feb 15, 2025
Anticipated Study Completion Date :
May 31, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Nasal Povidone-Iodine Decolonization Intervention

Intranasal povidone-iodine (PDI Profend) will be applied to the patients' noses 60 minutes before surgery to repair HELEF and approximately 12 hours after the first application. If the patient will have additional HELEF repair in the 6 month followup period, intranasal PVI will be applied in a similar manner for each procedure.

Drug: povidone-iodine topical ointment
Intranasal povidone-iodine will be applied to the lower anterior nares (i.e. nostril) of patients undergoing HELEF orthopedic repair.
Other Names:
  • Profend
  • No Intervention: Concurrent Control

    Standard of Care. This will be usual care at each participating site for subjects enrolled in the Baseline period.

    Outcome Measures

    Primary Outcome Measures

    1. Incidence of Complex (deep incisional or organ space) Staphylococcus aureus surgical site infection (SSI) [within 180 days of the initial surgical procedure for HELEF repair]

      Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network (NHSN) definitions for SSI found in the "Surgical Site Infection Event (SSI)" guide at https://www.cdc.gov/nhsn/pdfs/pscmanual/9pscssicurrent.pdf

    Secondary Outcome Measures

    1. Incidence of all Staphylococcus aureus SSI [within 180 days of the initial surgical procedure for HELEF repair]

      Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network (NHSN) definitions for SSI found in the "Surgical Site Infection Event (SSI)" guide at https://www.cdc.gov/nhsn/pdfs/pscmanual/9pscssicurrent.pdf

    2. Incidence of all Complex SSI [within 180 days of the initial surgical procedure for HELEF repair]

      Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network (NHSN) definitions for SSI found in the "Surgical Site Infection Event (SSI)" guide at https://www.cdc.gov/nhsn/pdfs/pscmanual/9pscssicurrent.pdf

    3. Incidence of all gram-negative Complex SSI [within 180 days of the initial surgical procedure for HELEF repair]

      Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network (NHSN) definitions for SSI found in the "Surgical Site Infection Event (SSI)" guide at https://www.cdc.gov/nhsn/pdfs/pscmanual/9pscssicurrent.pdf

    4. Incidence of cellulitis involving the surgical site [within 180 days of the initial surgical procedure for HELEF repair]

      Cellulitis is a common bacterial skin infection that causes redness, swelling, and pain in the infected area of the skin surrounding the surgical site of the HELEF repair.

    5. Clavien-Dindo assessment of postoperative complications scores [within 180 days of the initial surgical procedure for HELEF repair]

      The Clavien-Dindo assessment grades postoperative surgical complications from 1 to 5, with 5 being the worst outcome. Postoperative courses with no evidence of complications have no grade (a "0" for the purposes of this study). Clavien-Dindo assessment definitions found at: https://www.assessurgery.com/clavien-dindo-classification/

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Age > 18 years of age.

    • Is undergoing one or more procedures to address the included fractures listed below for one or more (at least one) HELEF at high-risk for SSI:

    • Open tibia fractures

    • Open femur fractures

    • Open or closed tibial plateau fractures

    • Open or closed tibial pilon fractures

    • Open or closed calcaneus fractures

    • Open or closed talus fractures

    • Open or closed foot fractures of any bone EXCEPT the toes

    • Open fibula fractures

    • Open rotational ankle fractures (malleoli)

    • Open or closed leg fractures associated with compartment syndrome

    • Examples of included procedures:

    • Excisional debridement of open fracture, femur and/or tibia

    • Intramedullary nail, tibia (open injury)

    • Intramedullary nail, femur (open injury)

    • Open reduction Pilon/Plafond fracture

    • Open reduction tibial plateau fracture

    • Open reduction calcaneal fracture

    • Open reduction Lisfranc/metatarsal associated with crush injury

    • Open reduction talus

    • External fixation, lower extremity tibia or femur associated with open fracture or compartment syndrome

    • Fasciotomy, lower extremity for compartment syndrome related to femur, tibia, or foot fracture

    • Lower extremity amputation related to HELEF

    Exclusion Criteria:
    • Documented or verbalized sensitivity or allergy to iodine or iodine-based contrast.

    • Known pregnancy in women.

    • Active bacterial infection at the HELEF site.

    • Incarcerated persons.

    • Persons who cannot follow up at the participating site (e.g., people who are homeless at the time of the injury or people with intellectual challenges who lack the social support for follow up visits).

    • Patients with facial fractures or other conditions that preclude nasal swabbing.

    • Patients who cannot consent, including patients with dementia, delirium, coma, impaired mental status, traumatic brain injury, and patients who are sedated or intubated.

    • Closed, isolated rotational ankle fractures

    • Patients who do not speak English or Spanish

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Emory University Atlanta Georgia United States 30303
    2 University of Indiana Indianapolis Indiana United States 46202
    3 University of Iowa Iowa City Iowa United States 52242
    4 Washington University Saint Louis Missouri United States 63110
    5 University of Texas Southwestern Dallas Texas United States 75235
    6 University of Utah Salt Lake City Utah United States 84108

    Sponsors and Collaborators

    • Loreen Herwaldt
    • Indiana University
    • University of Utah
    • Washington University School of Medicine
    • University of Texas
    • Emory University
    • PDI Healthcare
    • Centers for Disease Control and Prevention

    Investigators

    • Principal Investigator: Loreen Herwaldt, MD, University of Iowa

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Loreen Herwaldt, Professor, University of Iowa
    ClinicalTrials.gov Identifier:
    NCT05763602
    Other Study ID Numbers:
    • 202109074
    • U54CK000613
    First Posted:
    Mar 10, 2023
    Last Update Posted:
    Mar 13, 2023
    Last Verified:
    Mar 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    Yes
    Keywords provided by Loreen Herwaldt, Professor, University of Iowa
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 13, 2023